Comparison of the Effects of ShotBlocker, Virtual Reality Glasses and Cold Application in Subcutaneous Heparin Injection
NCT ID: NCT05833646
Last Updated: 2024-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2023-03-01
2023-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Three Different Local Cold Applications on Pain and Ecchymosis in Subcutaneous Heparin Injections
NCT04235244
Cold Application on the Subcutaneous Injection
NCT05771285
Perfusion Index in the Success of Peripheral Nerve Block
NCT02989896
Efficacy of Warming Garment in the Perioperative Period With Integrated Chemical Heat Packs to Maintain Normothermia
NCT02905708
Effectiveness of Dry Cold Application on Pain and Bruise at the Subcutaneous Injection Site Among Patients Admitted in ICU
NCT03233321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ShotBlocker Group
In control application, subcutaneous (SC) LMWH injection will be applied in patient's left abdomen with standard method on Post-op 0th day by the researcher. Intervention with ShotBlocker will be performed on the right abdomen site on post-op 1st day by the researcher. During subcutaneous LMWH injection with ShotBlocker, suitable injection site in right abdomen will be grasped by applying medium-weight pressure as ShotBlocker's obtuse touching points would touch the skin. In order to avoid ecchymosis and hematoma, it will be applied slowly for 10 seconds by entering from the middle point of ShotBlocker with a 90° angle. When injection is over, ShotBlocker will be removed 10 seconds will be waited. Removing the needle, the entry point will be applied light pressure with dry cotton for 10 seconds without any massage. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.
Group 1
In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
Virtual Reality Glasses (VRG) Group
Standard LMWH application will be performed on the left side for control on Post-op 0th day by the researcher.
Intervention with VRG will be performed on the right abdomen site on post-op 1st day. The researcher will show the patient a video 5 minutes before the injection providing them with virtual reality glasses, which will continue till the end of the operation, after which the glasses will be removed. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.
Group 2
In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
Cold Application Group
Standard heparin application will be performed on left side for control on post-op 0th day by the researcher. Intervention with cold application will be performed on the right abdomen site on post-op 1st day. Prior to the intervention, cold silica gel pack which stayed in the freezer for at least 2 hours will be placed on patient's injection site by wrapping up with towel and will be applied on the site for 5 minutes. After 5 minutes, the cold gel pack will be removed from the site and subcutaneous LMWH injection will be applied by the researcher. Following the removal of the injector, cold application will continue for another 2 minutes. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) after injection.
Group 3
In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group 1
In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
Group 2
In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
Group 3
In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 or over years of age
* Received 1x0,4 ml enoksaparin sodium treatment
* Experienced no complications during or after operation
* Normal values of thrombocyte (150.000-300.000), aPTT (25-35 sec) and INR (0.8-1.2) (Thrombocyte, INR and aPTT tests will be assessed in accordance with reference values of the kits that the hospital uses.)
* No infection, scar tissue or incision in abdomen site
* Received no parenteral treatment other than this site
* Not diagnosed with any sort of coagulation disorder
* No visual impairment to be able to wear VR glasses
* No allergy to cold
* No mental or neurological disability
* No audio-visual impairment disability to be able to watch the video
* Turkish speaking and comprehending
* Non-pregnant
* No hematological or allergic disease
* Willing to be hospitalized for 2 days
* Volunteer to participate in the research will constitute the research sample.
Exclusion Criteria
* Renounce from participating in the research
* Remove virtual reality glasses during or after operation
* Fail to hold the cold pack for necessary period of time
* Show signs of cold allergy during operation
* Change institutions or were discharged early during research
* Change dose of drugs within drug system
* Develop drawbacks in the abdomen site will be excluded from the research.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara Yildirim Beyazıt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ebru Erek Kazan
Assoc.Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hafize Güllü, MsN
Role: PRINCIPAL_INVESTIGATOR
Ankara Yildirim Beyazit University , Faculty of Health Sciences, Department of Nursing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara Yildirim Beyazit University Faculty of Health Sciences, Department of Nursing
Ankara, Çubuk, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-1790
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.